{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T19:04:04Z","timestamp":1773342244391,"version":"3.50.1"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T00:00:00Z","timestamp":1771804800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T00:00:00Z","timestamp":1771804800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Bethune Charitable Foundation: Shining China","award":["Z04JKM2023E040"],"award-info":[{"award-number":["Z04JKM2023E040"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82274173"],"award-info":[{"award-number":["82274173"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82204819"],"award-info":[{"award-number":["82204819"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"the \u201cShenlan\u201d talent project of Naval Medical University","award":["SL63"],"award-info":[{"award-number":["SL63"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1007\/s00228-025-03940-5","type":"journal-article","created":{"date-parts":[[2026,2,22]],"date-time":"2026-02-22T23:58:15Z","timestamp":1771804695000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Exploring potential biomarkers and constructing prediction models of osimertinib based on a retrospective study"],"prefix":"10.1007","volume":"82","author":[{"given":"Lili","family":"Cui","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mao","family":"Tang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"SuLi","family":"Liang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chen","family":"Bu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yunlei","family":"Yun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shouhong","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhipeng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xia","family":"Tao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,2,23]]},"reference":[{"issue":"2","key":"3940_CR1","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1097\/JTO.0000000000000033","volume":"9","author":"Y Shi","year":"2014","unstructured":"Shi Y, Au JS, Thongprasert S, Srinivasan S, Tsai CM, Khoa MT, Heeroma K, Itoh Y, Cornelio G, Yang PC (2014) A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology (PIONEER). J Thorac Oncol 9(2):154\u2013162. https:\/\/doi.org\/10.1097\/JTO.0000000000000033","journal-title":"J Thorac Oncol"},{"issue":"5","key":"3940_CR2","doi-asserted-by":"publisher","first-page":"497","DOI":"10.6004\/jnccn.2022.0025","volume":"20","author":"DS Ettinger","year":"2022","unstructured":"Ettinger DS, Wood DE, Aisner DL, Akerley W, Bauman JR, Bharat A, Bruno DS, Chang JY, Chirieac LR, D\u2019Amico TA, DeCamp M, Dilling TJ, Dowell J, Gettinger S, Grotz TE, Gubens MA, Hegde A, Lackner RP, Lanuti M, Lin J, Hughes M (2022) Non-Small cell lung cancer, version 3.2022, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw 20(5):497\u2013530. https:\/\/doi.org\/10.6004\/jnccn.2022.0025","journal-title":"J Natl Compr Canc Netw"},{"issue":"5","key":"3940_CR3","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1093\/annonc\/mdy474","volume":"30","author":"D Planchard","year":"2019","unstructured":"Planchard D, Popat S, Kerr K, Novello S, Smit EF, Faivre-Finn C, Mok TS, Reck M, Van Schil PE, Hellmann MD, Peters S (2019) Correction to: \u201cMetastatic non-small cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up.\u201d Ann Oncol 30(5):863\u2013870. https:\/\/doi.org\/10.1093\/annonc\/mdy474","journal-title":"Ann Oncol"},{"key":"3940_CR4","unstructured":"Guidelines of Chinese Society of Clinical Oncology (CSCO) (2021) Non-small cell lung cancer, China"},{"issue":"23","key":"3940_CR5","first-page":"1725","volume":"101","author":"Oncology Society of Chinese Medical Association, Chinese Medical Association Publishing House","year":"2021","unstructured":"Oncology Society of Chinese Medical Association, Chinese Medical Association Publishing House (2021) Chinese medical association guidelines for clinical diagnosis and treatment of lung cancer (Edition 2021) [J]. Natl Med J China 101(23):1725\u20131757","journal-title":"Natl Med J China"},{"key":"3940_CR6","doi-asserted-by":"publisher","DOI":"10.1177\/17588359211059874","volume":"13","author":"A Addeo","year":"2021","unstructured":"Addeo A, Hochmair M, Janzi U, Dudnik E, Charpidou A, P\u0142u\u017ca\u0144ski A, Ciuleanu T, Donev IS, Elbaz J, Aar\u00f8e J, Ott R, Peled N (2021) Treatment patterns, testing practices, and outcomes in the pre-FLAURA era for patients with EGFR mutation-positive advanced NSCLC: a retrospective chart review (REFLECT). Ther Adv Med Oncol 13:17588359211059874. https:\/\/doi.org\/10.1177\/17588359211059874","journal-title":"Ther Adv Med Oncol"},{"issue":"20","key":"3940_CR7","doi-asserted-by":"publisher","first-page":"5130","DOI":"10.1158\/1078-0432.CCR-16-0399","volume":"22","author":"P Ballard","year":"2016","unstructured":"Ballard P, Yates JW, Yang Z, Kim DW, Yang JC, Cantarini M, Pickup K, Jordan A, Hickey M, Grist M, Box M, Johnstr\u00f6m P, Varn\u00e4s K, Malmquist J, Thress KS, J\u00e4nne PA, Cross D (2016) Preclinical comparison of osimertinib with other EGFR-TKIs in EGFR-Mutant NSCLC brain metastases models, and early evidence of clinical brain metastases activity. Clin Cancer Res 22(20):5130\u20135140. https:\/\/doi.org\/10.1158\/1078-0432.CCR-16-0399","journal-title":"Clin Cancer Res"},{"key":"3940_CR8","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.78.3118","author":"T Reungwetwattana","year":"2018","unstructured":"Reungwetwattana T, Nakagawa K, Cho BC, Cobo M, Cho EK, Bertolini A, Bohnet S, Zhou C, Lee KH, Nogami N, Okamoto I, Leighl N, Hodge R, McKeown A, Brown AP, Rukazenkov Y, Ramalingam SS, Vansteenkiste J (2018) CNS response to osimertinib versus standard epidermal growth factor receptor tyrosine kinase inhibitors in patients with untreated EGFR-mutated advanced non-small-cell lung cancer. J Clin Oncol. https:\/\/doi.org\/10.1200\/JCO.2018.78.3118","journal-title":"J Clin Oncol"},{"issue":"2","key":"3940_CR9","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.annonc.2019.10.026","volume":"31","author":"K Park","year":"2020","unstructured":"Park K, Vansteenkiste J, Lee KH, Pentheroudakis G, Zhou C, Prabhash K, Seto T, Voon PJ, Tan DSW, Yang JCH, Wang J, Babu KG, Nakayama Y, Alip A, Chua KLM, Cheng JC, Senan S, Ahn YC, Kim TY, Ahn HK, Douillard JY (2020) Pan-Asian adapted ESMO clinical practice guidelines for the management of patients with locally-advanced unresectable non-small-cell lung cancer: a KSMO-ESMO initiative endorsed by CSCO, ISMPO, JSMO, MOS, SSO and TOS. Annals Oncol : Official J Eur Soc Med Oncol 31(2):191\u2013201. https:\/\/doi.org\/10.1016\/j.annonc.2019.10.026","journal-title":"Annals Oncol : Official J Eur Soc Med Oncol"},{"key":"3940_CR10","doi-asserted-by":"publisher","first-page":"101637","DOI":"10.1016\/j.tranon.2023.101637","volume":"31","author":"Q Ye","year":"2023","unstructured":"Ye Q, Xu Y, Zhao J, Gao X, Chen M, Pan R, Zhong W, Wang M (2023) Osimertinib improves overall survival of EGFR-mutant NSCLC patients with leptomeningeal metastases. Transl Oncol 31:101637. https:\/\/doi.org\/10.1016\/j.tranon.2023.101637","journal-title":"Transl Oncol"},{"issue":"2","key":"3940_CR11","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1056\/NEJMoa1713137","volume":"378","author":"JC Soria","year":"2018","unstructured":"Soria JC, Ohe Y, Vansteenkiste J, Reungwetwattana T, Chewaskulyong B, Lee KH, Dechaphunkul A, Imamura F, Nogami N, Kurata T, Okamoto I, Zhou C, Cho BC, Cheng Y, Cho EK, Voon PJ, Planchard D, Su WC, Gray JE, Lee SM, FLAURA Investigators (2018) Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. N Engl J Med 378(2):113\u2013125. https:\/\/doi.org\/10.1056\/NEJMoa1713137","journal-title":"N Engl J Med"},{"key":"3940_CR12","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.ejca.2019.11.006","volume":"125","author":"NB Leighl","year":"2020","unstructured":"Ramalingam SS., Vansteenkiste, J., Planchard, D., Cho, B. C., Gray, J. E., Ohe, Y., Zhou, C., Reungwetwattana, T., Cheng, Y., Chewaskulyong, B., Shah, R., Cobo, M., Lee, K. H., Cheema, P., Tiseo, M., John, T., Lin, M. C., Imamura, F., Kurata, T., Todd, A., \u2026 FLAURA Investigators (2020). Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC. The New England journal of medicine, 382(1), 41\u201350. https:\/\/doi.org\/10.1056\/NEJMoa1913662","journal-title":"Eur J Cancer (Oxf Engl : 1990)"},{"key":"3940_CR13","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.1005626","volume":"12","author":"MA Barbieri","year":"2022","unstructured":"Leighl, N. B., Karaseva, N., Nakagawa, K., Cho, B. C., Gray, J. E., Hovey, T., Walding, A., Ryd\u00e9n, A., & Novello, S. (2020). Patient-reported outcomes from FLAURA: Osimertinib versus erlotinib or gefitinib in patients with EGFR-mutated advanced non-small-cell lung cancer. European journal of cancer (Oxford, England : 1990), 125, 49\u201357. https:\/\/doi.org\/10.1016\/j.ejca.2019.11.006","journal-title":"Front Oncol"},{"issue":"1","key":"3940_CR14","doi-asserted-by":"publisher","first-page":"19555","DOI":"10.1038\/s41598-022-23834-1","volume":"12","author":"Y Yin","year":"2022","unstructured":"Barbieri, M. A., Sorbara, E. E., Cicala, G., Santoro, V., Cutroneo, P. M., Franchina, T., Santarpia, M., Silvestris, N., & Spina, E. (2022). Safety profile of tyrosine kinase inhibitors used in non-small-cell lung cancer: An analysis from the Italian pharmacovigilance database. Frontiers in oncology, 12, 1005626. https:\/\/doi.org\/10.3389\/fonc.2022.1005626","journal-title":"Sci Rep"},{"issue":"18","key":"3940_CR15","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.1056\/NEJMoa1411817","volume":"372","author":"PA J\u00e4nne","year":"2015","unstructured":"Yin Y., Shu, Y., Zhu, J., Li, F., & Li, J. (2022). A real-world pharmacovigilance study of FDA Adverse Event Reporting System (FAERS) events for osimertinib. Scientific reports, 12(1), 19555. https:\/\/doi.org\/10.1038\/s41598-022-23834-1","journal-title":"N Engl J Med"},{"key":"3940_CR16","doi-asserted-by":"publisher","first-page":"S1067","DOI":"10.1016\/j.annonc.2022.07.1254","volume":"33","author":"AV Veelen","year":"2022","unstructured":"J\u00e4nne, P. A., Yang, J. C., Kim, D. W., Planchard, D., Ohe, Y., Ramalingam, S. S., Ahn, M. J., Kim, S. W., Su, W. C., Horn, L., Haggstrom, D., Felip, E., Kim, J. H., Frewer, P., Cantarini, M., Brown, K. H., Dickinson, P. A., Ghiorghiu, S., & Ranson, M. (2015). AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer. The New England journal of medicine, 372(18), 1689\u20131699. https:\/\/doi.org\/10.1056\/NEJMoa1411817","journal-title":"Ann Oncol"},{"key":"3940_CR17","doi-asserted-by":"crossref","unstructured":"Veelen A V, Veerman M G D, Verschueren M, et al. 1130P Real-world data of osimertinib (osi) for the treatment of metastatic epidermal growth factor receptor (EGFR+) non-small cell lung cancer (NSCLC) patients (pts), with a focus on age, body mass index (BMI) and trough levels[J]. Annals of Oncology, 2022, 33: S1067-S1068.","DOI":"10.1016\/j.annonc.2022.07.1254"},{"issue":"1","key":"3940_CR18","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.lungcan.2015.01.026","volume":"88","author":"M Takeda","year":"2015","unstructured":"Astrazeneca pharmaceuticals. Tagrisso (osimertinib) [package insert]. U.S. Food and Drug Administration website. Revised April 2018. Available at: www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/208065s008lbl.pdf.","journal-title":"Lung Cancer"},{"key":"3940_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2015.01.026","volume-title":"Mortality and burden of disease attributable to selected major","author":"World Health Organization Global Health Risks","year":"2009","unstructured":"Takeda, M., Okamoto, I., & Nakagawa, K. (2015). Pooled safety analysis of EGFR-TKI treatment for EGFR mutation-positive non-small cell lung cancer. Lung cancer (Amsterdam, Netherlands), 88(1), 74\u201379. https:\/\/doi.org\/10.1016\/j.lungcan.2015.01.026"},{"issue":"Pt E","key":"3940_CR20","first-page":"1","volume":"100","author":"IARC Working Group on the Evaluatio","year":"2012","unstructured":"World Health Organization Global Health Risks: Mortality and Burden of Disease Attributable to Selected Major Risks World Health Organization, Geneva (2009)","journal-title":"IARC Monogr Eval Carcinog Risks Hum"},{"key":"3940_CR21","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.canep.2016.09.011","volume":"45","author":"C Scoccianti","year":"2016","unstructured":"IARC Working Group on the Evaluation of Carcinogenic Risks to Humans (2012). Personal habits and indoor combustions. IARC monographs on the evaluation of carcinogenic risks to humans, 100(Pt E), 1\u2013538.","journal-title":"Cancer Epidemiol"},{"issue":"1","key":"3940_CR22","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1038\/s41572-018-0014-7","volume":"4","author":"HK Seitz","year":"2018","unstructured":"Cogliano, V. J., Baan, R., Straif, K., Grosse, Y., Lauby-Secretan, B., El Ghissassi, F., Bouvard, V., Benbrahim-Tallaa, L., Guha, N., Freeman, C., Galichet, L., & Wild, C. P. (2011). Preventable exposures associated with human cancers. Journal of the National Cancer Institute, 103(24), 1827\u20131839. https:\/\/doi.org\/10.1093\/jnci\/djr483","journal-title":"Nat Rev Dis Primers"},{"issue":"4","key":"3940_CR23","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/j.canep.2016.09.011","volume":"27","author":"D Wu","year":"2003","unstructured":"Scoccianti, C., Cecchini, M., Anderson, A. S., Berrino, F., Boutron-Ruault, M. C., Espina, C., Key, T. J., Leitzmann, M., Norat, T., Powers, H., Wiseman, M., & Romieu, I. (2016). European Code against Cancer 4th Edition: Alcohol drinking and cancer. Cancer epidemiology, 45, 181\u2013188. https:\/\/doi.org\/10.1016\/j.canep.2016.09.011","journal-title":"Alcohol Res Health"},{"issue":"1","key":"3940_CR24","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1053\/j.gastro.2014.10.042","volume":"148","author":"G Szabo","year":"2015","unstructured":"Seitz, H. K., Bataller, R., Cortez-Pinto, H., Gao, B., Gual, A., Lackner, C., Mathurin, P., Mueller, S., Szabo, G., & Tsukamoto, H. (2018). Alcoholic liver disease. Nature Reviews Disease Primers, 4(1), 16. https:\/\/doi.org\/10.1038\/s41572-018-0014-7","journal-title":"Gastroenterology"},{"key":"3940_CR25","unstructured":"Wu, D., & Cederbaum, A. I. (2003). Alcohol, oxidative stress, and free radical damage. Alcohol Research & Health, 27(4), 277\u2013284."},{"issue":"1","key":"3940_CR26","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1038\/ajg.2016.517","volume":"112","author":"PY Kwo","year":"2017","unstructured":"Szabo, G. (2015). Gut-liver axis in alcoholic liver disease. Gastroenterology, 148(1), 30\u201336. https:\/\/doi.org\/10.1053\/j.gastro.2014.10.042","journal-title":"Am J Gastroenterol"},{"issue":"2","key":"3940_CR27","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1111\/acer.13197","volume":"69","author":"SP Roche","year":"2004","unstructured":"Vatsalya, V., Song, M., Schwandt, M. L., Cave, M. C., Barve, S. S., George, D. T., Ramchandani, V. A., & McClain, C. J. (2016). Effects of Sex, Drinking History, and Omega-3 and Omega-6 Fatty Acids Dysregulation on the Onset of Liver Injury in Very Heavy Drinking Alcohol-Dependent Patients. Alcoholism, clinical and experimental research, 40(10), 2085\u20132093. https:\/\/doi.org\/10.1111\/acer.13197","journal-title":"Am Fam Physician"},{"key":"3940_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.cca.2024.120028","volume":"566","author":"C Bu","year":"2025","unstructured":"Kwo, P. Y., Cohen, S. M., & Lim, J. K. (2017). ACG Clinical Guideline: Evaluation of Abnormal Liver Chemistries. American Journal of Gastroenterology, 112(1), 18-35. https:\/\/doi.org\/10.1038\/ajg.2016.517","journal-title":"Clin Chim Acta"},{"key":"3940_CR29","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1016\/j.jare.2024.07.019","volume":"72","author":"Z Wang","year":"2025","unstructured":"Roche, S. P., & Kobos, R. (2004). Jaundice in the adult patient. American family physician, 69(2), 299-304.","journal-title":"J Adv Res"},{"issue":"1","key":"3940_CR30","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1056\/NEJMoa1913662","volume":"382","author":"SS Ramalingam","year":"2020","unstructured":"Bu, C., Jiang, L., Cui, L., Tang, M., Song, X., Zhao, Y., Liang, Z., Ye, L., Nian, J., Gao, S., Tao, X., Wang, Z., & Chen, W. (2025). LC-MS\/MS method for quantification of 23 TKIs in Plasma: Assessing the relationship between anlotinib trough concentration and toxicities. Clinica chimica acta; international journal of clinical chemistry, 566, 120028. https:\/\/doi.org\/10.1016\/j.cca.2024.120028","journal-title":"N Engl J Med"},{"issue":"24","key":"3940_CR31","doi-asserted-by":"publisher","first-page":"1827","DOI":"10.1093\/jnci\/djr483","volume":"103","author":"VJ Cogliano","year":"2011","unstructured":"Wang, Z., Liu, Z., Cui, L., Sun, J., Bu, C., Tang, M., Li, M., Gao, S., Chen, W., & Tao, X. (2025). Disturbance of bile acids profile aggravates the diarrhea induced by capecitabine through inhibiting the Wnt\/\u03b2-catenin pathway. Journal of advanced research, 72, 591\u2013604. https:\/\/doi.org\/10.1016\/j.jare.2024.07.019","journal-title":"J Natl Cancer Inst"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-025-03940-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00228-025-03940-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-025-03940-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T09:53:47Z","timestamp":1773309227000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00228-025-03940-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,23]]},"references-count":31,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["3940"],"URL":"https:\/\/doi.org\/10.1007\/s00228-025-03940-5","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,23]]},"assertion":[{"value":"19 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The protocol of this study was approved by the Ethics Committee of Second Affiliated Hospital of Naval Medical University (Shanghai Changzheng Hospital) (No. 2022-031). Every patient consented to participate this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"<!--Emphasis Type='Bold' removed-->Human ethics and consent to participate"}},{"value":"All authors have consented to publish this manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Clinical trial number"}}],"article-number":"83"}}